Skip to main content
Top

Breast Cancer Research and Treatment

Issue 3/2008

Content (15 Articles)

Review

Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC)

Ander Urruticoechea, Monica Arnedos, Geraldine Walsh, Mitch Dowsett, Ian E. Smith

Preclinical Study

Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases

Dmitry A. Turbin, Samuel Leung, Maggie C. U. Cheang, Hagen A. Kennecke, Kelli D. Montgomery, Steven McKinney, Diana O. Treaba, Niki Boyd, Lynn C. Goldstein, Sunil Badve, Allen M. Gown, Matt van de Rijn, Torsten O. Nielsen, C. Blake Gilks, David G. Huntsman

Preclinical Study

The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome

Andrew R. Green, Claire Burney, Christopher J. Granger, E. Claire Paish, Somaia El-Sheikh, Emad A. Rakha, Desmond G. Powe, R. Douglas Macmillan, Ian O. Ellis, Eleni Stylianou

Preclinical Study

Alteration of expression levels of the oxidative phosphorylation system (OXPHOS) in breast cancer cell mitochondria

Lorenza Putignani, Salvatore Raffa, Roberta Pescosolido, Laura Aimati, Fabrizio Signore, Maria Rosaria Torrisi, Paola Grammatico

Preclinical Study

Characterization of the role of CD8+T cells in breast cancer immunity following mammaglobin-A DNA vaccination using HLA-class-I tetramers

Ankit Bharat, Nicholas Benshoff, Timothy P. Fleming, Jill R. Dietz, William E. Gillanders, T. Mohanakumar

Preclinical Study

Hypoxia-inducible factor 1α is closely linked to an aggressive phenotype in breast cancer

Yutaka Yamamoto, Mutsuko Ibusuki, Yasuhiro Okumura, Teru Kawasoe, Kazuharu Kai, Kenichi Iyama, Hirotaka Iwase

Preclinical Study

Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables

Woo Chul Noh, Yang Hee Kim, Min Suk Kim, Jae Soo Koh, Hyun-Ah Kim, Nan Mo Moon, Nam-Sun Paik

Preclinical study

Favourable long-term results after surgical removal of lung metastases of breast cancer

Masataka Yoshimoto, Keiichiro Tada, Seiichiro Nishimura, Masujiro Makita, Takuji Iwase, Fujio Kasumi, Sakae Okumura, Yukitoshi Sato, Ken Nakagawa

Preclinical Study

Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells

Jennifer L. Gilmore, Jeffrey A. Scott, Zhor Bouizar, Alex Robling, Sarah E. Pitfield, David J. Riese II, John Foley

Preclinical Study

Effects of exon-deleted estrogen receptor β transcript variants on growth, apoptosis and gene expression of human breast cancer cell lines

Oliver Treeck, Ingolf Juhasz-Boess, Claus Lattrich, Felicitas Horn, Regina Goerse, Olaf Ortmann

Epidemiology

Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue

Vanesa Martinez, Susan Kennedy, Padraig Doolan, Patrick Gammell, Helena Joyce, Elaine Kenny, Jai Prakash Mehta, Eoin Ryan, Robert O’Connor, John Crown, Martin Clynes, Lorraine O’Driscoll

Clinical Trial

Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival

Masakazu Toi, Seigo Nakamura, Katsumasa Kuroi, Hiroji Iwata, Shinji Ohno, Norikazu Masuda, Mikihiro Kusama, Kosuke Yamazaki, Kazuhumi Hisamatsu, Yasuyuki Sato, Masahiro Kashiwaba, Hiroshi Kaise, Masafumi Kurosumi, Hitoshi Tsuda, Futoshi Akiyama, Yasuo Ohashi, Yuichi Takatsuka

Letter to the editor

Post-diagnosis statin use and breast recurrence sites in early stage breast cancer survivors

Hakan Harputluoglu, Omer Dizdar, Fatih Karaahmet, Kadri Altundag

Led to the Editor

Absence of CHEK2 1100delC mutation in familial breast cancer cases from a South American population

Patricio González-Hormazábal, Víctor G. Castro, Rafael Blanco, Fernando Gómez, Octavio Peralta, Enrique Waugh, Teresa Bravo, Jose M. Reyes, Lilian Jara

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine